Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens

Cell Rep. 2023 Mar 28;42(3):112160. doi: 10.1016/j.celrep.2023.112160. Epub 2023 Mar 2.

Abstract

Immunogens that elicit broadly neutralizing antibodies targeting the conserved receptor-binding site (RBS) on influenza hemagglutinin may serve as candidates for a universal influenza vaccine. Here, we develop a computational model to interrogate antibody evolution by affinity maturation after immunization with two types of immunogens: a heterotrimeric "chimera" hemagglutinin that is enriched for the RBS epitope relative to other B cell epitopes and a cocktail composed of three non-epitope-enriched homotrimers of the monomers that comprise the chimera. Experiments in mice find that the chimera outperforms the cocktail for eliciting RBS-directed antibodies. We show that this result follows from an interplay between how B cells engage these antigens and interact with diverse helper T cells and requires T cell-mediated selection of germinal center B cells to be a stringent constraint. Our results shed light on antibody evolution and highlight how immunogen design and T cells modulate vaccination outcomes.

Keywords: CP: Immunology; affinity maturation; antigen capture; antigen valency; helper T cell; immune focusing; immunogen design; in silico; mechanism; selection.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Hemagglutinins
  • Humans
  • Influenza Vaccines*
  • Influenza, Human*
  • Mice
  • Vaccination

Substances

  • Influenza Vaccines
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Hemagglutinins
  • Hemagglutinin Glycoproteins, Influenza Virus